Trial Profile

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB CART19.1 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms MB-CART19.1 r/r CD19+ BCM
Sponsors Miltenyi Biotec GmbH

Most Recent Events

19 Jun 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
22 Nov 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
22 Nov 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com